Rimegepant

Rimegepant is an oral antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM). It inhibits cAMP production stimulated by α-CGRP in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Romegepant has been approved by the U.S. FDA for the acute treatment of migraine.